The Role of In Vitro Detection of Drug-Specific Mediator-Releasing Cells to Diagnose Different Phenotypes of Severe Cutaneous Adverse Reactions

Jettanong Klaewsongkram 1,12* Supranee Buranapraditkun 1,12 Pattarawat Thantiworsat,1,2 Pawnee Rerknimitr 1,2,3 Papapit Tuchinda 4, Leena Chularojanamontri 1,5 Ticha Rerkpattanapipat 5, Kumutnart Chanprapaph 6, Wareeporn Disphanurat 7, Panlop Chakkavittumrong 8, Napatra Tovanabutra 9, Chutika Srisitthyakorn 10, Yuttana Srinoulprasert 1,10 Chonlaphat Sukasem 11,11 Yuda Chongpison 1,2

1Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, The Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand
2King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
3Division of Dermatology, Department of Medicine, Faculty of Medicine, The Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand
4Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
5Allergy Immunology and Rheumatology Division, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
6Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
7Division of Dermatology, Department of Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
8Dermatologic Division, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand
9Division of Dermatology, Department of Medicine, Phramongkutklao Hospital, Phramongkutklao College of Medicine, Bangkok, Thailand
10Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
11Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
12Center for Excellence in Biostatistics, Faculty of Medicine, The Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand

ABSTRACT

Propose: The purpose of this study was to investigate panels of enzyme-linked immunospot assays (ELISpot) to detect drug-specific mediator releasing cells for confirming culprit drugs in severe cutaneous adverse reactions (SCARs).

Methods: Frequencies of drug-induced interleukin-22 (IL-22), interferon-gamma (IFN-γ), and granzyme-B (GrB)-releasing cells were measured by incubating peripheral blood mononuclear cells (PBMCs) from SCAR patients with the culprit drugs. Potential immunoadjuvants were supplemented to enhance drug-induced mediator responses.

Results: Twenty-seven patients, including 9 acute generalized exanthematous pustulosis (AGEP), 10 drug reactions with eosinophilia and systemic symptoms, and 8 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) were recruited. The average frequencies of drug-induced IL-22-, IFN-γ-, and GrB-releasing cells were 35.5±16.3, 33.0±7.1, and 164.8±43.1 cells/million PBMCs, respectively. The sensitivity of combined IFN-γ/IL-22/GrB ELISpot was higher than that of IFN-γ ELISpot alone for culprit drug detection in all SCAR subjects (77.8% vs 51.9%, P < 0.01). The measurement of drug-induced IL-22- and IFN-γ
releasing cells confirmed the culprit drugs in 77.8% of AGEP. The measurement of drug-induced IFN-γ- and GrB-releasing cells confirmed the culprit drugs in 62.5% of SJS/TEN. Alpha-galactosylceramide supplementation significantly increased the frequencies of drug-induced IFN-γ-releasing cells.

**Conclusion:** The measurement of drug-induced IFN-γ-releasing cells is the key for identifying culprit drugs. The additional measurement of drug-induced IL-22-releasing cells enhances ELISpot sensitivity to identify drug-induced AGEP, while the measurement of drug-induced GrB-releasing cells could have a role in SJS/TEN. ELISpot sensitivity might be improved by supplementary alpha-galactosylceramide.

**Trial Registration:** ClinicalTrials.gov Identifier: [NCT02574988](https://clinicaltrials.gov/ct2/show/NCT02574988)

**Keywords:** Drug allergy, diagnosis, in vitro; T cell; cytokine; IFN-γ

**INTRODUCTION**

The identification and confirmation of culprit drugs in patients who experience drug-induced severe cutaneous adverse reactions (SCARs) is difficult. Most of the time, the culprit drugs suspected are not re-challenged, so the diagnostic value of the test cannot be validated. The sensitivity of skin tests to identify culprit drugs is limited, and there are risks of exacerbating the allergic reaction.\(^1\)\(^2\) In vitro diagnostic tests have been introduced to identify culprit drugs, for example, the lymphocyte transformation test (LTT) and the measurement of drug-specific mediator release using enzyme-linked immunospot assays (ELISpot), which have been reported to be more sensitive than LTT.\(^3\)\(^4\) Interferon-gamma (IFN-γ) is the cytokine most often used to study drug-specific T cell responses.\(^5\)\(^6\) As several cytokines play roles in the pathogenesis of SCARs, the diagnostic values of IFN-γ ELISpot in different phenotypes of SCAR are still limited.

Several factors might affect the results of drug-specific mediator responses in a real-world situation, such as the elapsed time since the last exposure, systemic steroid administration before having blood drawn, and SCAR phenotypes.\(^7\)\(^8\) It has been proposed that LTT should be performed during the recovery phase, since the assay may yield false-negative results during the acute drug allergic phase.\(^9\)\(^10\) However, ELISpot data showed that the measurement of drug-specific mediator-releasing cells would be helpful at both acute and recovery phases, although sensitivity would decrease after 2 years since the last reaction.\(^4\)\(^11\) Taken together, the exploration of the appropriate panel of drug-specific mediators to yield the maximum sensitivity of the in vitro test is essential.

The measurement of drug-specific IFN-γ-releasing cells has most commonly been used with the ELISpot technique to identify culprit drugs. However, other mediators also play a role in T-cell-mediated drug reactions.\(^12\) There is evidence that cytotoxic signals, such as granulysin, perforin/granzyme B (GrB), and Fas/Fas ligand, are elevated in not only Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), but also in drug reaction with eosinophilia and systemic symptoms (DRESS).\(^13\)\(^14\) Furthermore, the roles of interleukin (IL)-17 family cytokines, such as IL-17 and IL-22, have been demonstrated in inflammatory skin diseases such as pustular psoriasis and acute generalized exanthematous pustulosis (AGEP).\(^15\)\(^16\) The measurement of these mediators released from peripheral blood mononuclear cells (PBMCs) in patients with SCAR would probably be helpful in the identification of culprit drugs.
In real-world practice, several factors could affect the sensitivity of drug-specific mediator measurements. Many regulatory molecules, particularly immune checkpoint inhibitors, have influences on the magnitude of immune responses. T-cell immunoglobulin and mucin domain 3 (TIM3) is known as a checkpoint receptor and exhaustion marker with both positive and inhibitory functions; reduced expression of TIM3 has been demonstrated in Th1 cells in drug-induced maculopapular exanthema.\textsuperscript{20-21} The administration of immune checkpoint inhibitors, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA4), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1), could activate cytotoxic T cell responses in malignancies, but also lead to the development of immune-mediated cutaneous reactions.\textsuperscript{20,21} There is a report that blockade of the PD-1/PD-L1 pathway could induce IFN-\(\gamma\) secretion from drug-specific T cells.\textsuperscript{22} Additionally, alpha-galactosylceramide (\(\alpha\)-GalCer) has been shown to enhance cellular immune responses, mainly via increasing the functions of natural killer T (NKT) cells.\textsuperscript{23} It would be interesting to explore whether the manipulation of these molecules could enhance the sensitivity of \textit{in vitro} testing for drug allergy diagnosis.

The purpose of this study was to evaluate the diagnostic values of IFN-\(\gamma\), IL-22, and GrB ELISpot assay as a confirmatory test in patients with a history of drug-induced SCARs and the potential benefit of \textit{in vitro} adjuvant supplementation.

**MATERIALS AND METHODS**

Twenty-seven patients with a history of drug-induced SCARs were enrolled in the study. These patients were part of the Thailand Severe Cutaneous Adverse Reactions (ThaiSCARs) cohort. The diagnosis of SCARs was confirmed as probable or definite SJS/TEN, DRESS, or AGEP according to the RegiSCAR diagnostic criteria.\textsuperscript{24-26} The culprit drugs suspected were selected based on those with the highest Naranjo score.\textsuperscript{27}

**Culprit drug preparations**

The tested drugs for ELISpot assay were prepared from the intravenous drugs available in King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand. Ten mg of each culprit drug powder was measured, and dissolved in 1 ml of sterile distilled water, then allowed to settle for 1 hour before adjusting for ELISpot assay concentrations (Supplementary Table S1). The solutions prepared were used immediately after preparation, and the remaining should not be kept for further use. Pure drug substances for which intravenous preparation was not available were purchased from Sigma-Aldrich (St Louis, MO, USA).

**ELISpot**

PBMCs were separated by Ficoll-Hypaque density gradient centrifugation. The frequencies of drug-induced mediator releasing cells were determined using ELISpot assay kits (human IL-22 single-color ELISpot [Mabtech, Stockholm, Sweden] and human IFN-\(\gamma\)/GrB double-color ELISpot [Cellular Technology Limited, Cleveland, OH, USA]). Briefly, 96-well polyvinylidene fluoride membrane plates were coated for 16 hours at 4°C with 5 \(\mu\)g/mL anti-IFN-\(\gamma\) antibody, anti-GrB antibody, and anti-IL-22 antibody provided in the kit and blocked with R10 medium (RPMI1640 supplemented with 100 U/mL penicillin, 100 U/mL streptomycin, and 10% heat-inactivated fetal bovine serum) for 1 hour at room temperature. PBMCs (2.0–2.5 \(\times\) 10\(^5\) in 100 \(\mu\)L) were incubated for 48 hours at 37°C in 5% CO\(_2\) with the culprit drugs in the presence or absence of \(\alpha\)-GalCer (100 ng/mL; Abcam, Cambridge, UK), anti-CTLA4 (10 \(\mu\)g/mL; Merck Millipore, Burlington, MA, USA), anti-TIM-3 (10 \(\mu\)g/mL; Merck Millipore), or anti-PD-1 (5...
µg/mL; Biolegend, San Diego, CA, USA). Plates were later washed 6 times with phosphate-buffered saline/Tween 0.05%, and incubated for 2 hours at room temperature with the corresponding biotinylated antibody, and then washed extensively. Spot-forming units (SFU) were developed using streptavidin-alkaline phosphatase, incubated for 1 hour at room temperature, and washed extensively before adding the substrate. The numbers of spots were analyzed using an ImmunoSpot S6 Ultimate Analyzer (Cellular Technology Limited) as shown in Fig. 1. The results were expressed as the highest numbers of SFU/10⁶ PBMCs on stimulation with 2 concentrations of the culprit drugs tested, after subtracting the value obtained from PBMCs cultured without drugs (unstimulated control). The drug concentrations used for the ELISpot assay listed in Supplementary Table S1 were generally in the same range as therapeutic serum concentrations, as mentioned in our previous study.²⁸

The frequencies of IL-22-, IFN-γ-, and GrB-releasing cells when incubating PBMCs with the irrelevant non-culprit drugs were also measured in 18 out of the 27 SCAR subjects to evaluate non-specific mediator responses as a control group shown in Fig. 2. The irrelevant non-culprit drugs used in the control group were the culprits suspected in other SCAR subjects, but were not the drugs implicated in the particular SCAR subjects. The ELISpot assay was considered positive if the frequencies of drug-induced IL-22-, IFN-γ-, and GrB-releasing cells in 27 SCAR subjects upon incubating PBMCs with the culprit drugs were higher than the upper limit of the 95% confidence interval (CI) for mean mediator-releasing cells in the non-allergic control group (18.7, 17.2, and 97.7 SFU/10⁶ PBMCs, respectively).

**Statistical analysis**

The average frequencies of drug-induced mediator-releasing cells are expressed as means and 95% CI. Student’s *t*-test was used to compare the frequencies of drug-induced mediator-releasing cells among different phenotypes. McNemar’s test was used to comparatively analyze the sensitivity between different types of ELISpot assays. All statistical calculations...
were analyzed using Prism version 8 software (GraphPad Prism, San Diego, CA, USA). *P* values < 0.05 were considered statistically significant.

**Ethics**

PBMCs employed in this experiment were cryopreserved specimens from patients enrolled in the ThaiSCAR registry. The registry was approved by the Ethics and Research Committee of the Faculty of Medicine, Chulalongkorn University, and the study was conducted in accordance with the Declaration of Helsinki. The informed consent for both study participation and publication of identifying information in an online open-access publication was obtained from all participants. The ThaiSCAR study is registered at ClinicalTrials.gov (NCT02574988).

**RESULTS**

A total of 27 patients who developed drug-induced SCARs (9 AGEP, 10 DRESS, and 8 SJS/TEN) were included in this study. Seventeen patients (63.0%) were female, with an average age of 54.1 ± 4.8 years. The average ELISpot assay latency (the time from drug reaction onset to PBMC collection for ELISpot assay) was 10.6 ± 2.3 days as shown in Table.

The average frequencies of drug-induced IL-22-, IFN-γ-, and GrB-releasing cells upon incubating PBMCs with the culprit drugs in all SCAR phenotypes were 35.5 ± 16.3, 33.0 ± 7.1, and 164.8 ± 43.1 SFU/10⁶ cells, respectively. The average frequencies of drug-induced IL-22-releasing cells were significantly higher in AGEP subjects than in non-AGEP SCAR subjects, while those of drug-induced IFN-γ-releasing cells were significantly lower (*P* = 0.01 and 0.04, respectively) as shown in Fig. 2. A significant difference was demonstrated in the frequencies of drug-induced IFN-γ-releasing cells between AGEP and DRESS (12.7 ± 5.3 SFU/10⁶ cells vs 45.0 ± 11.9 SFU/10⁶ cells, *P* = 0.03).
### Table. Clinical characteristics of 27 patients with severe cutaneous adverse reactions in this study and results of drug-induced mediator-releasing cell measurement by ELISpot (SFU/10^6 PBMCs)

| Patient No. | Sex | Age (yr) | Phenotype | Culprit drugs | Underlying diseases | ELISpot assay latency (days) | Concurrent steroid | IL-22 (SFU/10^6 PBMCs) | IFN-γ (SFU/10^6 PBMCs) | GrB |
|-------------|-----|----------|-----------|---------------|---------------------|----------------------------|-------------------|----------------------|----------------------|-----|
| 1           | F   | 87       | AGEP      | Vancomycin    | DM                  | 5                          | None              | 90                   | 0                    | 56  |
| 2           | F   | 69       | AGEP      | Vancomycin    | Cellulitis, HT      | 6                          | None              | 68                   | 8                    | 16  |
| 3           | F   | 65       | AGEP      | Meropenem     | None                | 3                          | Dexa 20 mg/day for 1 day | 0                    | 0                    | 110 |
| 4           | F   | 50       | AGEP      | Amoxicillin/ clavulanate | Psoriasis     | 5                          | None              | 297                  | 4                    | 249 |
| 5           | M   | 62       | AGEP      | IRZE          | Tuberculosis        | 25                         | None              | 28                   | 0                    | 16  |
| 6           | F   | 88       | AGEP      | Ciprofloxacin | HT                  | 4                          | None              | 0                    | 5                    | 85  |
| 7           | F   | 82       | AGEP      | Pipercillin/ tazobactam | DM, HT     | 2                          | Pred 60 mg/day for 2 days | 0                    | 37                   | 37  |
| 8           | M   | 88       | AGEP      | Ciprofloxacin | DM, HT              | 6                          | None              | 340                  | 20                   | 30  |
| 9           | F   | 76       | AGEP      | Omeprazole    | None                | 7                          | None              | 0                    | 40                   | 90  |
| 10          | M   | 36       | DRESS     | Co-trimoxazole | HIV infection       | 10                         | None              | 20                   | 5                    | 545 |
| 11          | F   | 63       | DRESS     | Allopurinol   | Hyperuricemia       | 5                          | Dexa 5 mg/d for 3 days | 15                   | 20                   | 980 |
| 12          | M   | 18       | DRESS     | Co-trimoxazole | None                | 48                         | Dexa 10 mg/day for 5 days then Pred 60 mg/day for 1 day | 5                    | 0                    | 80  |
| 13          | F   | 65       | DRESS     | Allopurinol   | HT, gout            | 2                          | Dexa 24 mg/d for 1 day | 0                    | 75                   | 50  |
| 14          | F   | 35       | DRESS     | Leflunomide   | Rheumatoid arthritis | 39                         | Pred 20 mg/d for 90 days | 0                   | 80                   | 300 |
| 15          | M   | 17       | DRESS     | Sulfadiazine  | Toxoplasmosis       | 14                         | None              | 0                    | 0                    | 85  |
| 16          | F   | 15       | DRESS     | Co-trimoxazole | Systemic vasculitis | 4                          | None              | 5                    | 50                   | 170 |
| 17          | M   | 29       | DRESS     | Co-trimoxazole | HIV infection       | 36                         | None              | 10                   | 80                   | 140 |
| 18          | F   | 17       | DRESS     | Phenytin      | Ruptured AVM        | 5                          | Pred 60 mg/d for 5 days | 0                    | 100                  | 140 |
| 19          | M   | 19       | DRESS     | Phenytin      | Seizure             | 5                          | Dexa 15 mg/d for 5 days | 0                    | 40                   | 20  |
| 20          | F   | 65       | SJS       | Allopurinol   | Gout                | 1                          | None              | 0                    | 8                    | 0   |
| 21          | M   | 87       | SJS       | Allopurinol   | Gout                | 7                          | Dexa 20 mg/d for 1 day | 30                   | 40                   | 160 |
| 22          | F   | 67       | SJS       | Allopurinol   | Gout                | 5                          | None              | 20                   | 110                  | 650 |
| 23          | M   | 74       | TEN       | Meropenem     | Brain abscess       | 7                          | Dexa 5mg/d for 7 days | 0                    | 10                   | 210 |
| 24          | F   | 72       | SJS       | Levofloxacin  | MCTD, lymphoma      | 7                          | None              | 10                   | 0                    | 50  |
| 25          | F   | 74       | SJS       | Phenytin      | Intracranial hemorrhage | 2                         | Dexa 24mg/d for 1 day | 20                   | 50                   | 40  |
| 26          | M   | 36       | SJS       | Co-trimoxazole | HIV infection, chronic hepatitis C | 16                         | Pred 40 mg/d for 3 days | 0                    | 110                  | 120 |
| 27          | F   | 51       | SJS       | Phenytin      | Breast cancer with brain metastasis | 10                         | Pred 40 mg/d for 14 days then Pred 20 mg/d for 14 days | 0                    | 0                    | 0   |

Bold text indicates positive ELISpot assays, ELISpot assay latency.

ELISpot, enzyme-linked immunospot assay; SFU, spot-forming units; PBMCs, peripheral blood mononuclear cells; IL, interleukin; IFN-γ, interferon-gamma; GrB, granzyme B; AGEP, acute generalized exanthematous pustulosis; DM, diabetes mellitus; HT, hypertension; Dexa, dexamethasone; IRZE, isoniazid/rifampicin/pyrazinamide/ethambutol (anti-tuberculosis agents); DRESS, drug reaction with eosinophilia and systemic symptoms; HIV, human immunodeficiency virus; Pred, prednisolone; AVM, arteriovenous malformation; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; MCTD, mixed connective tissue disease.

Univariate and multivariate linear regressions were conducted to evaluate whether drug groups (antibiotics vs. non-antibiotics) and SCAR phenotypes (AGEP vs. non-AGEP) could influence cytokine release patterns. The results in Supplementary Fig. S1 demonstrate that the frequencies of drug-induced IL-22-releasing cells were significantly higher in AGEP subjects than in non-AGEP subjects by 83.9 (95% CI, 20.2–447.7) SFU/10^6 PBMCs. After adjusting for the antibiotic group, the difference in IL-22 levels between patients with AGEP and those with non-AGEP remains statistically significant, with the mean difference of 77.2 (95% CI, 5.4–148.9) SFU/10^6 PBMCs (P< 0.05).

### Diagnostic values of the measurement of drug-specific mediator-releasing cells to identify suspected culprit drugs

According to the data in Table, the measurement of drug-induced IL-22-, IFN-γ-, and GrB-releasing cells yielded sensitivities of 33.3%, 51.9%, and 44.4%, respectively, for culprit drug identification in all SCAR subjects if each mediator was separately analyzed. It is worth...
noting that almost all GrB-positive subjects (except for patients number 3 and 23) could be diagnosed by measuring other mediators as well.

The results in Fig. 3 indicate that the sensitivity of the 3-mediator combination to confirm the culprit drugs in overall SCAR subjects was significantly higher than that of IFN-\(\gamma\) measurement alone (77.8% vs. 51.9%, respectively, \(P\) value < 0.01). The culprit drugs in AGEP, DRESS, and SJS/TEN could be identified in 33.3%, 70.0%, and 50.0% of patients, respectively, by using the IFN-\(\gamma\) ELISpot assay, while 88.9%, 80.0%, and 62.5% could be identified using a combination of IL-22, IFN-\(\gamma\), and GrB ELISpot assays.

The combined measurement of drug-induced IL-22- and IFN-\(\gamma\)-releasing cells identified the culprit drugs in 77.8%, 80.0%, 50.0%, and 70.4% of AGEP, DRESS, SJS/TEN, and all SCAR patients, respectively. The combined measurement of drug-induced IFN-\(\gamma\)- and GrB-releasing cells identified the culprit drugs in 55.6%, 80.0%, 62.5%, and 66.7% of AGEP, DRESS, SJS/TEN, and all SCAR patients, respectively. The combined measurement of drug-induced IL-22 and GrB identified the culprit drugs in only 48.1% of all SCAR subjects (data not shown).

The average frequency of drug-induced IL-22-releasing cells upon incubating PBMCs with the culprit drugs was 35.5 ± 16.3 SFU/10^6 cells, while that upon incubating the culprit drugs with potential adjuvants ranged from to 22.4 ± 8.9 to 36.6 ± 14.1 SFU/10^6 cells as shown in Fig. 4. The average frequency of drug-induced IFN-\(\gamma\) releasing cells upon incubation with the culprit drugs alone was 33.0 ± 7.1 SFU/10^6 cells, while supplementation with \(\alpha\)-GalCer, anti-TIM-3, and anti-PD-1 increased the frequency to 72.3 ± 18.5*, 63.4 ± 18.5, and 83.9 ± 38.2 SFU/10^6 cells, respectively (\(P\) = 0.02 compared to no adjuvant supplementation). The average frequency of drug-induced GrB-releasing cells upon incubating PBMCs with the culprit drugs was 164.8 ± 43.1 SFU/10^6 cells, while that upon incubating the culprit drugs with various potential adjuvants ranged from 77.9 ± 16.9 to 153.3 ± 53.1 SFU/10^6 cells.

Fig. 3. The sensitivity of different ELISpot assays to identify the culprit drugs in severe cutaneous adverse reactions (\(n = 27\)). The sensitivity of the three-mediator combination to confirm the culprit drugs in overall SCAR subjects was significantly higher than that of IFN-\(\gamma\) measurement alone (77.8% versus 51.9%, respectively). ELISpot, enzyme-linked immunospot assays; SCARs, severe cutaneous adverse reactions; AGEP, acute generalized exanthematous pustulosis; DRESS, drug reaction with eosinophilia and systemic symptoms; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; IFN-\(\gamma\), interferon-gamma; IL, interleukin; GrB, granzyme B.

\*\(P\) value < 0.01.
DISCUSSION

Culprit drug confirmation is a difficult task, particularly in drug-induced SCARs. Since drug provocation is generally contraindicated in SCARs and the sensitivity of skin tests to identify the culprit drugs is inadequate, the roles of in vitro diagnostic tests are currently being explored. IFN-γ is the cytokine most frequently measured from T-cells in patients with a history of drug allergy. However, the sensitivity of the IFN-γ ELISpot assay is not yet satisfactory. Many obstacles limit the roles of in vitro testing; for example, different SCAR phenotypes have variable mediator expression patterns, and in certain phenotypes, especially DRESS, it is difficult to identify the culprit drugs during the acute allergic phase. Therefore, this study was designed to explore a combination of mediator panels to improve the sensitivity for identifying the culprit drugs in real-world practice in various SCAR phenotypes.

According to our study, the measurement of drug-induced IFN-γ-releasing cells is still the key to culprit drug identification in SCARs. The results of this study support the previous literature that the measurement of drug-induced IFN-γ-releasing cells can identify the culprit drugs in at least half of patients with drug-induced SCARs, particularly in those with DRESS or SJS/TEN.4,29 However, the sensitivity of the test is rather low in those with AGEP.28

Our study demonstrates different patterns of drug-induced mediator-releasing cells in patients with various SCAR phenotypes, and shows that the combination of 3 mediators (IL-22, IFN-γ, and GrB) can enhance the sensitivity of ELISpot to identify the culprit drugs in 77.8% of all SCAR
subjects. Interestingly, we found that the measurement of drug-induced IL-22-releasing cells played a predominant role in identifying drug-induced AGEP. In fact, the sensitivity of combined IFN-\(\gamma\) and IL-22 ELISpot for culprit drug identification (70.4%) in SCARs was almost as high as the measurement of 3 mediators (77.8%), but it was slightly lower in SJS/TEN. Our study confirms earlier findings that not only SJS/TEN but also DRESS involve GrB in disease pathogenesis.\(^\text{14}\) However, drug-induced GrB-releasing cells were often co-expressed with other mediators in this study. As a result, the additional advantage of GrB measurement together with IFN-\(\gamma\) for culprit drug confirmation was only modest, compared to the measurement of drug-specific IFN-\(\gamma\) alone. The IFN-\(\gamma\)/GrB combination might be worth considering if the test was focused on SJS/TEN.

According to this study, the supplementation of various potential adjuvants augmented drug-induced IFN-\(\gamma\) release, but had minimal effect on IL-22 and GrB production. Interestingly, we found that the \(\alpha\)-GalCer supplement significantly enhanced the frequencies of drug-induced IFN-\(\gamma\)-releasing cells, followed by anti-TIM-3 and anti-PD-1 supplementation, while supplementation with anti-CTLA4 appeared to have little benefit. The fact that the immune checkpoint inhibitors, other than \(\alpha\)-GalCer, failed to substantially enhance drug-specific in vitro immune responses probably due to the small number of tested subjects in each phenotype. Besides, further experiments are needed to explore the appropriate incubation time and the concentrations of the adjuvants of interest to achieve optimal responses for each specific cytokine.

It is well documented that various T cell subsets, such as cytotoxic T-cells, Th1, and Th2 cells, participate in the pathogenesis of SCARs.\(^\text{30}\) According to our study, several cell types capable of producing IL-22, such as Th17 cells, Th22 cells, \(\gamma\)\(\delta\) T cells, NK cells, NKT cells, and innate lymphoid cells, might play a role in AGEP as well.\(^\text{31,32}\) Nonetheless, the clinical benefit of \(\alpha\)-GalCer supplement to increase the sensitivity of IFN-\(\gamma\) ELISpot assay for culprit drug identification needed to be confirmed in further studies. Since \(\alpha\)-GalCer can stimulate IFN-\(\gamma\) production from NKT cells,\(^\text{33}\) the roles of NKT cells in the pathogenesis of SCARs, particularly in DRESS and SJS/TEN, should also be explored.

There are several limitations to this preliminary study. Further studies with a larger sample size are needed to confirm the results. Additional research should be performed to measure the frequencies of these mediators at various time points after drug reaction onset to find the most appropriate timeline yielding a maximum sensitivity of each cytokine in different SCAR phenotypes. The measurement of other cytokines in the IL-17 family may also be helpful for AGEP diagnosis. Granulysin indeed plays roles in the pathogenesis of SCARs, particularly in SJS/TEN and DRESS.\(^\text{34}\) However, the incubation time for granulysin expression is too long for a conventional ELISpot assay to detect drug-specific granulysin release.\(^\text{35}\) High GrB background levels in the control subjects were observed which diminished the sensitivity of the test. The analyses of IFN-\(\gamma\) and GrB ELISpot assays in separated wells may be required to optimize the measurement of drug-induced GrB releasing cells. Whether supplementary adjuvants could increase the sensitivity of the IFN-\(\gamma\) ELISpot assay for culprit drug confirmation without reducing the specificity of the test is yet to be determined.

In conclusion, our study demonstrated differential mediator expressions among 3 main SCAR phenotypes, and supported the diagnostic value of IFN-\(\gamma\) ELISpot assay as the major tool to identify culprit drugs. While an additional GrB measurement might be helpful in SJS/TEN, the measurement of drug-specific IL-22-releasing cells should be encouraged for culprit drug identification in AGEP. The beneficial effects of in vitro tests for enhancing the detection of drug-induced IFN-\(\gamma\)-releasing cells in SCARs need further verification.
ACKNOWLEDGMENTS

This study has been supported by the Skin and Allergy Research Unit, Chulalongkorn University, and Health Systems Research Institute, Thailand (grant no. 62-043).

SUPPLEMENTARY MATERIALS

Supplementary Table S1
Drug concentrations used for ELISpot in this study

Click here to view

Supplementary Fig. S1
The impacts of SCAR phenotypes and drug groups on the mean differences of drug-induced mediator releasing cells. The frequencies of drug-induced IL-22 releasing cells in AGEP subjects were significantly higher than those in non-AGEP subjects.

Click here to view

REFERENCES

1. Co Minh HB, Bousquet PJ, Fontaine C, Kværdiane V, Demoly P. Systemic reactions during skin tests with beta-lactams: a risk factor analysis. J Allergy Clin Immunol 2006;117:466-8. PUBMED | CROSSREF

2. Liccardi G, D’Amato G, Canonica GW, Salzillo A, Piccolo A, Passalacqua G. Systemic reactions from skin testing: literature review. J Investig Allergol Clin Immunol 2006;16:75-8. PUBMED

3. Haw WY, Polak ME, McGuire C, Erlewyn-Lajeunesse M, Ardern-Jones MR. In vitro rapid diagnostic tests for severe drug hypersensitivity reactions in children. Ann Allergy Asthma Immunol 2016;117:61-6. PUBMED | CROSSREF

4. Suthumchai N, Srinoulprasert Y, Thantiworasit P, Rerknimitr P, Tuchinda P, Chularojanamontri L, et al. The measurement of drug-induced interferon gamma-releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions. J Eur Acad Dermatol Venereol 2018;32:992-8. PUBMED | CROSSREF

5. Copaescu A, Gibson A, Li Y, Trubiano JA, Phillips EJ. An updated review of the diagnostic methods in delayed drug hypersensitivity. Front Pharmacol 2021;11:573573. PUBMED | CROSSREF

6. Halevy S, Cohen AD, Grossman N. Clinical implications of in vitro drug-induced interferon gamma release from peripheral blood lymphocytes in cutaneous adverse drug reactions. J Am Acad Dermatol 2005;52:254-61. PUBMED | CROSSREF

7. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007;62:1439-44. PUBMED | CROSSREF

8. Klaewsongkram J, Thantiworasit P, Suthumchai N, Rerknimitr P, Sukasem C, Tuchinda P, et al. In vitro test to confirm diagnosis of allopurinol-induced severe cutaneous adverse reactions. Br J Dermatol 2016;175:994-1002. PUBMED | CROSSREF

9. Polak ME, Belgi G, McGuire C, Pickard C, Healy E, Friedmann PS, et al. In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. Br J Dermatol 2013;168:539-49. PUBMED | CROSSREF
10. Cabañas R, Calderón O, Ramírez E, Fiandor A, Caballero T, Heredia R, et al. Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment. Clin Exp Allergy 2018;48:325-33.

11. Tanvarasethee B, Buranapraditkun S, Klaewsongkram I. The potential of using enzyme-linked immunospot to diagnose cephalosporin-induced maculopapular exanthems. Acta Derm Venereol 2013;93:66-9.

12. Kuechler PC, Britschgi M, Schmid S, Hari Y, Grabscheid B, Pichler WJ. Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy 2004;59:613-22.

13. Su SC, Chung WH. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions. Toxins (Basel) 2014;6:194-210.

14. Yang F, Chen SA, Wu X, Zhu Q, Luo X. Overexpression of cytotxic proteins correlates with liver function impairment in patients with drug reaction with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol 2018;28:13-25.

15. Cavani A, Pennino D, Eyerich K. Th17 and Th22 in skin allergy. Chem Immunol Allergy 2012;96:39-44.

16. Speeckaert R, Lambert J, Grine L, Van Gele M, De Schepper S, van Geel N. The many faces of interleukin-17 in inflammatory skin diseases. Br J Dermatol 2016;175:892-901.

17. Sullivan A, Wang E, Farrell J, Whitaker P, Faulkner L, Peckham D, et al. β-Lactam hypersensitivity involves expansion of circulating and skin-resident T_{H}22 cells. J Allergy Clin Immunol 2018;141:235-249.e8.

18. Banerjee H, Kane LP. Immune regulation by Tim-3. F1000 Res 2018;7:316.

19. Fernandez-Santamaria R, Palomares F, Salas M, Doña I, Bogas G, Ariza A, et al. Expression of the Tim3-galectin-9 axis is altered in drug-induced maculopapular exanthema. Allergy 2019;74:1769-79.

20. Plachouri KM, Vryzaki E, Georgiou S. Cutaneous adverse events of immune checkpoint inhibitors: a summarized overview. Curr Drug Saf 2019;14:14-20.

21. Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 2017;41:125-8.

22. Gibson A, Ogese M, Sullivan A, Wang E, Saide K, Whitaker P, et al. Negative regulation by PD-L1 during drug-specific priming of IL-22-secreting T cells and the influence of PD-1 on effector T cell function. J Immunol 2014;192:2611-21.

23. Ghinnagow R, Cruz LJ, Macho-Fernandez E, Faveeuw C, Trottein F. Enhancement of adjuvant functions of natural killer T cells using nanovector delivery systems: application in anticancer immune therapy. Front Immunol 2017;8:879.

24. Sidoroff A, Halevy S, Bavinck NJ, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)–a clinical reaction pattern. J Cutan Pathol 2001;28:113-9.

25. Kardaun SH, Sidoroff A, Valevre-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007;156:609-11.

26. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.

27. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
28. Klaewsongkram J, Sukasem C, Thantiworasit P, Suthumchai N, Rerknimitr P, Tuchinda P, et al. Analysis of HLA-B allelic variation and IFN-γ ELISpot responses in patients with severe cutaneous adverse reactions associated with drugs. J Allergy Clin Immunol Pract 2019;7:219-227.e4.
PUBMED | CROSSREF

29. Porebski G. In vitro assays in severe cutaneous adverse drug reactions: are they still research tools or diagnostic tests already? Int J Mol Sci 2017;18:1737.
PUBMED | CROSSREF

30. Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. Drug Saf 2019;42:973-92.
PUBMED | CROSSREF

31. Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. Annu Rev Immunol 2015;33:747-85.
PUBMED | CROSSREF

32. Colonna M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 2009;31:15-23.
PUBMED | CROSSREF

33. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs. Nat Immunol 2002;3:867-74.
PUBMED | CROSSREF

34. Chen CB, Abe R, Pan RY, Wang CW, Hung SI, Tsai YG, et al. An updated review of the molecular mechanisms in drug hypersensitivity. J Immunol Res 2018;2018:6431694.
PUBMED | CROSSREF

35. Won HK, Lee JW, Song WJ, Klaewsongkram J, Kang MG, Park HK, et al. Lamotrigine-induced toxic epidermal necrolysis confirmed by in vitro granulysin and cytokine assays. Asia Pac Allergy 2014;4:253-6.
PUBMED | CROSSREF